NR 546 Week 6 Addiction Medication Table QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+.

NR 546 ADDICTION TABLE WEEK 6

, Drug Name Indication Half-life Notable Side Effects (link to Initial Dosing
Neurotransmitter(s) Affected (T1/2), NT or affected brain circuit) Considerations
Target Symptoms Metabolism Specific lifespan
(CYP 450 considerations (age,
enzyme) pregnancy, breastfeeding)

Buprenorphine Indication: Half-life:   Headache, Initial dosing:
(Subutex) constipation, nausea Day 1: 8 mg
  Maintenance 24-42   Oral hypoesthesia, Day 2: 12-16 mg Days 3-
treatment of opioid hours glossodynia 7: Increase in increments
dependence CYP450:   Orthostatic of 4 mg, maximum 32 mg
  Maintenance CYP3A4 hypotension Considerations:
treatment of opioid   Implant specific:
dependence in insertion site pain,   Use with
patients who have pruritis, erythema caution in elderly
achieved and   Respiratory and those with
sustainced depression cardiac
prolonged clinical   Hepatotoxicity impairment
stability on low-to-   Maybe
moderate doses of a preferable to
transmucosal methadone in
buprenorphine- pregnant women
containing product   Neonatal
  Moderate to withdrawal may
severe opioid use occur
disorder in patients   Drug is found in
who have initiated breast milk,
treatment with a recommended to
transmucosal DC drug or bottle
buprenorphine- feed
containing product,   Safety and
followed by dose efficacy has not
adjustment for a been established
minimum of 7 days